Fortekor Plus
benazepril / pimobendan
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Fortekor Plus. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Fortekor Plus.
For practical information about using Fortekor Plus, animal owners/keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Fortekor Plus
|
Agency product number |
EMEA/V/C/002804
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QC09BX90
|
Publication details | |
---|---|
Marketing-authorisation holder |
Elanco GmbH
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
08/09/2015
|
Contact address |
Heinz-Lohmann-Str. 4 |
Product information
20/07/2020 Fortekor Plus - EMEA/V/C/002804 - R/0018
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
ACE inhibitors, combinations
Therapeutic indication
For the treatment of congestive heart failure due to atrioventricular valve insufficiency or dilated cardiomyopathy in dogs.